# Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma

> clinical trial · VERIFIED · 2026-06-18

Status: RECRUITING · Sponsor: Rong Tao · Condition: Extranodal NK/T-cell Lymphoma

- Company: Rong Tao
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07502768

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.